Biventricular cardiac dynamic shape: genetics and cardiometabolic disease associations

Authors and affiliations

Richard Burns[1,2,3,4], William J. Young[2,3], Kulsuma Uddin[2], Steffen E Petersen[2,3,4], Julia Ramírez*[2,5,6], Alistair A Young*^[1], Patricia B Munroe*^[2,3,4]

1. School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
2. William Harvey Research Institute, Queen Mary University London, Charterhouse Square, London, UK
3. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London, UK
4. NIHR Barts Biomedical Research Centre, Queen Mary of University London, Charterhouse Square, London, UK
5. Aragon Institute of Engineering Research, University of Zaragoza, Zaragoza, Spain
6. Centro de Investigación Biomédica en Red – Bioingeniería, Biomateriales y Nanomedicina, Zaragoza, Spain

*Indicates joint supervisors

^ indicates corresponding authors

Abstract

Background: Genetic studies using cardiac magnetic resonance (CMR) imaging have identified loci related to cardiac shape, but most focus on static morphology. The value of a dynamic cardiac shape atlas capturing both shape and function remains unknown.

Methods: A dynamic shape atlas comprising CMR-derived shape models at end-diastole and end-systole was combined with genetic and outcome data in 36,992 UK Biobank participants. Dynamic shape principal components (PCs) describing >1% of variance were characterized, and tested for associations with prevalent and incident cardiometabolic diseases, including ischemic heart disease (IHD), heart failure (HF), significant atrioventricular block (AVB), and atrial fibrillation (AF), and independent predictive power alongside standard CMR measures. Genome-wide association studies (GWAS) were performed to identify candidate genes and biological pathways, and polygenic risk scores (PRS) were assessed for disease associations. Mendelian randomization (MR) was performed to test causality of observed disease associations.

Results: We identified 14 dynamic cardiac shape PCs capturing 83.3% of total dynamic cardiac shape variance. These PCs captured distinct functional remodeling patterns such as variation in annular plane systolic excursion, while remaining only modestly correlated with standard CMR measures. All 14 PCs were associated with at least one incident cardiometabolic disease, with the strongest associations observed for incident IHD, HF, and AVB. Notably, incorporating dynamic shape PCs improved the prediction of incident IHD beyond standard CMR measures. GWAS identified 75 genetic loci associated with dynamic shape, including 14 variants previously unreported for cardiac traits, and candidate genes demonstrated enrichment in pathways related to cardiac development and contractile function. PRS derived from dynamic shape loci were significantly associated with multiple outcomes, most prominently HF. MR identified significant causal relationships between several PCs and cardiometabolic disease.

Conclusions: Dynamic cardiac shape features capture aspects of cardiac structure and function not fully represented by standard CMR measures. These features are strongly associated with incident cardiometabolic disease and provide new insights into the genetic architecture of cardiac remodeling.

Keywords: biventricular, dynamic cardiac shape and function, cardiometabolic disease, genome-wide association study

Clinical perspective:

What is new?
- Genetic and outcome relationships with a dynamic statistical shape model capturing both left and right ventricles at end-diastole and end-systole.
- Demonstration of incremental value over existing cardiac shape models, through capture of functional remodeling not represented by standard imaging measures.
- Identification of genetic susceptibility loci for dynamic cardiac shape, including 14 variants not previously reported for cardiac traits.

What are the clinical implications?
- The results enhance our understanding of the genetic architecture of dynamic cardiac shape and function in the general population and clarify their relationships with other cardiovascular endophenotypes and incident cardiometabolic diseases.
- Newly identified candidate genes expand the biological pathways implicated in cardiac remodeling and provide targets for future functional and mechanistic studies.
- The improved prediction of incident cardiometabolic disease, particularly ischemic heart disease, achieved by adding dynamic shape PCs to traditional CMR measures suggests potential value for their inclusion in evaluation of patients.

Introduction

The relationships between disease and cardiac morphology are bidirectional, in that disease can affect cardiac morphology through remodeling, and morphology can influence risk of cardiac disease incidence through physiological feedback mechanisms. For example, in ischemic heart disease (IHD) impaired blood flow may trigger myocardial remodeling, including hypertrophy or fibrosis[1–4], but pre-existing ventricular hypertrophy may conversely increase myocardial oxygen demand leading to ischemic conditions [5,6]. Cardiac structure and function measurements are therefore critical not only for diagnosing cardiovascular disease, but also for understanding disease risk mechanisms, pathogenesis, and prognosis[7,8]. However, standard measures such as ventricular volumes, masses, wall thicknesses, and ejection fraction do not capture all the morphological information present in modern cardiac imaging examinations.

Statistical cardiac shape atlas scores have established relationships with clinically meaningful measures[9–12], demonstrate stronger associations with prevalent disease than standard measures[11,13], and independently predict incident cardiovascular events[14]. However, the biological interpretation of the main drivers of shape variation, disease-shape relationships, and their genetic underpinnings remain limited. In particular, understanding the genetic basis of three-dimensional cardiac shape and motion may provide important insights into mechanisms underlying disease development.

Standard imaging-derived measures have a substantial genetic basis, including left and right ventricular end-diastolic (ED) and end-systolic (ES) volumes, myocardial mass, ejection fraction, myocardial strain, wall thickness, and sphericity[15–25]. Polygenic risk scores (PRS) derived from these traits have shown predictive value for cardiometabolic diseases, including cardiomyopathies[26–28], heart failure[29,30], atrial fibrillation[31–33], and type 2 diabetes mellitus[31,34,35]. More complex imaging-derived phenotypes have further expanded locus discovery, including regional wall thickness[25,36], trabecular complexity quantified by fractal dimension[37], and latent phenotypes derived from machine learning approaches[38–40]. Our previous work demonstrated that ED biventricular shape atlas scores have a significant genetic basis, with 43 associated loci[41]. However, analysis of coupled ED-ES shape and function, which utilizes information across the cardiac cycle and can better capture associations with cardiac functional disease, remains unexplored.

In this study, we investigated the relationships between a dynamic shape atlas, combining ED and ES shape in both left and right ventricles[42], and both prevalent and incident cardiometabolic disease in 36,992 participants of the UK Biobank, and evaluated the additive value of these phenotypes beyond standard measures in predictive models. We performed genome-wide association studies (GWAS), gene-burden testing, and downstream bioinformatic analyses to characterize the genetic basis of

dynamic cardiac shape and compared findings with our previously published ED-only shape GWAS[41].

We constructed PRS and conducted Mendelian randomization (MR) analyses to explore potential

causal relationships between genetically determined shape variation and cardiometabolic disease.

We hypothesized that dynamic cardiac shape phenotypes capture complementary structural and

functional information that enables identification of novel loci, provides insight into cardiac

remodeling mechanisms, and improves prediction of incident cardiometabolic disease beyond

standard imaging measures.

Methods

Data availability

112 All UK Biobank (UKB) data are available upon application (www.ukbiobank.ac.uk). Summary GWAS

113 statistics will be publicly available through the GWAS catalog (https://www.ebi.ac.uk/gwas) on

114 publication.

Study population and cardiac phenotyping

UK Biobank is a large prospective cohort of approximately 500,000 participants aged 40-69 years at

recruitment, with extensive demographic, clinical, lifestyle, and genetic data. Genotype data were

available for 488,377 individuals, generated using the UK BiLEVE and UK Biobank Axiom arrays. Study

design, genotyping, and quality control procedures have been described previously[43,44].

This study included cardiovascular magnetic resonance (CMR) imaging data from 45,683 participants,

which has been described previously[45]. Briefly, images were acquired on a 1.5T wide-bore scanner

(MAGNETOM Aera, Siemens Healthcare) using ECG-gating. Short-axis cine images covered both

ventricles with 8 mm slice thickness and 2 mm inter-slice gap (TR=2.6msec, TE=1.10msec),

interpolated to 50 phases per cardiac cycle. Long-axis cine images (2-, 3-, and 4- chamber views)

were acquired with 6 mm slice thickness (TR 2.7 ms, TE 1.16 ms).

Image analysis and dynamic shape atlas construction

The automated image analysis and shape atlas pipeline has been described previously[42]. Briefly,

short- and long-axis cine images were analyzed using Circle cvi42 (version 5.11 1505, Circle

Cardiovascular Imaging Inc., Calgary, Canada), using deep learning convolutional neural networks to

segment left ventricular (LV) endocardial and epicardial surfaces and right ventricular (RV)

endocardial surfaces. Valve landmarks for the mitral, tricuspid, and aortic valves were also

automatically extracted from long-axis views.

Biventricular subdivision surface meshes were generated at ED and ES using a non-rigid

diffeomorphic registration framework[46]. Short- and long-axis contours were first aligned to correct

for breath-hold misregistration, after which a template mesh was iteratively deformed to minimize

contour-to-surface distances while preserving diffeomorphic properties.

A statistical shape atlas was constructed by aligning ED meshes using generalized Procrustes

alignment[47] (excluding scaling to preserve size variation). The same transformation was applied to

both ED and ES meshes, preserving individual-specific ED-ES displacement patterns. ED and ES were

concatenated into a single vector per individual, and principal component analysis (PCA) was applied.

Fourteen dynamic cardiac shape PCs explaining >1% of total variance each (83.3% cumulative

variance) were retained, capturing joint morphological and functional variation across the cohort.

Shape quality control

Quality control procedures were performed to exclude cases in which the shape modeling process

failed, as described previously[42]. Briefly, cases with incomplete information needed to construct a 3D

shape model were excluded. Outlier shape models (chamber volumes exceeding 5 IQR) at ED or ES

were excluded prior to PCA. After PCA, shape score outliers exceeding 3 IQR in Mahalanobis distance

were excluded, and models with residual distance between the model surface and the PCA

representation exceeding 3 IQR were excluded.

Associations with conventional CMR measures and ED shape atlas

151 To assess relationships between dynamic shape PCs and standard CMR-derived measures, Pearson

152 correlations were computed for left and right ventricular volumes, masses, and ejection fractions.

153 Associations between dynamic shape PCs and cardiometabolic disease risk factors were calculated

154 similarly. Correlations with previously reported ED-only shape PCs[41] were also calculated to compare

155 static and dynamic atlases. Analyses were performed in R (version 4.3.1).

Disease association analyses

Associations between dynamic shape PCs and cardiometabolic disease were assessed for six well-

represented cardiometabolic diseases encompassing the different aspects of cardiac pathology in the

UK Biobank: atrial fibrillation (AF), significant atrioventricular block (AVB), heart failure (HF), IHD,

stroke, and type 2 diabetes (T2D). Multivariable logistic regression was used for prevalent disease

and Cox proportional hazards models for incident disease. Covariates, selected through stepwise

regression, included age at imaging, sex, height, body mass index (BMI), systolic and diastolic blood

pressure (averaged between automated and manual readings and adjusted for medication use),

serum high-density cholesterol (HDL), low-density lipoprotein (LDL) and mean triglyceride levels,

smoking and alcohol consumption (*Supplementary Table 1*). Missing covariate data were imputed

using the MICE[48], version 3.16.0) imputation package in R. Significant associations were defined at P

< 0.0083 (Bonferroni corrected at 0.05/6 diseases tested). Disease information was obtained from

hospital episode statistics data through UKB. ICD9, ICD10 and OPCS-4 codes were used to define

each disease (*Supplementary Table 2*). Prevalent and incident disease were defined using the date of

each participant's CMR imaging and the date of disease diagnosis.

Incident disease prediction: contribution of dynamic shape PCs beyond standard CMR measures

We tested whether incorporating dynamic cardiac shape PCs alongside standard CMR measures

improves prediction of incident cardiometabolic disease compared with models based on standard

CMR measures alone. Cox proportional hazards regression was used to construct two models for

each outcome.

The baseline model included standard CMR measures (left and right ventricular ED and ES volumes,

myocardial masses, ejection fractions, stroke volumes, and global circumferential and longitudinal

strain), together with established clinical covariates: sex, age, height, BMI, SBP and DBP, smoking

status, alcohol consumption, serum HDL, LDL and triglyceride levels. The extended model included

dynamic cardiac shape PCs in addition to the CMR measures and covariates retained from the

baseline model.

Separate prediction cohorts were defined within UK Biobank for each cardiometabolic outcome (AF,

AVB, HF, IHD, stroke, and T2D). Participants with a diagnosis of the relevant disease prior to their UK

Biobank imaging assessment date were excluded. Incident disease was defined using linked

electronic health record ICD codes (*Supplementary Table 2*).

A penalized Cox proportional hazards regression model framework with elastic net regularization

within R glmnet[49,50] was used to model time to event for incident cardiometabolic diseases with

equal lasso and ridge penalties to balance variable selection and coefficient shrinkage. The optimal

regularization parameter was selected using internal cross-validation within the training data. Two

models were created; the first a CMR model which combined clinical covariates identified to be

significantly associated with each disease through stepwise regression (*Supplementary Table 1*) and

CMR measures; and the second with these same variables as well as dynamic cardiac shape PCs.

Model performance was assessed using five-fold cross validation, calculating predictive performance

using concordance index (C-index). C-index variability, non-parametric bootstrap resampling was

performed (with 1,000 samples), and the 95% confidence intervals are reported alongside the C-

index.

Genetic analyses

A more detailed description of genetic analyses can be found in *Supplementary Methods*. Heritability of dynamic shape PCs was estimated in 36,992 unrelated white European participants with high-quality imaging data, no previous history of major cardiovascular disease, and a left ventricular ejection fraction of >40%, using BOLT-REML[51] version 2.3. GWAS were performed for each PC using a linear mixed model method (BOLT-LMM[52], version 2.4.1), testing 558,994 variants (minor allele frequency ≥1% and INFO >0.3), adjusting for age, sex, height, BMI, blood pressure, heart rate, array type and the top 10 genetic principal components. Genome-wide significance was defined as $P < 5\times10^{-8}$. A genomic signal was defined as the most significant (lead) SNV and all SNVs within a 1mb window in linkage disequilibrium (LD) $r^2 > 0.1$. Population stratification and confounding were assessed using LD score software (LDSC)[53], v1.0.1. Secondary signals were identified using GCTA conditional analysis[54], version 1.94.1.

Functional annotation and pathway analyses

Candidate genes were prioritized using variant effect prediction (VEP)[55–57], expression quantitative trait locus (eQTL) colocalization analysis[58], transcriptome-wide association studies[59], Hi-C long-range chromatin interactions[60–62], Polygenic Priority Score (PoPS)[63], literature review, and mouse knockout phenotypes (*Supplementary methods*)[64]. Candidate genes were queried using Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS)[65] to perform functional enrichment analysis. Significant enrichment was defined as an adjusted False Discovery Rate P < 0.05.

Rare variant analysis

We used Regenie[66] (v4.0) to assess the contribution of rare genetic variants to dynamic cardiac shape PCs, and prespecified variant masks and annotations were used. Leave one variant out (LOVO) analysis was performed to assess whether significant results were driven by single or multiple rare variants (*Supplementary methods*).

Genetic relationship with end-diastolic shape atlas

We assessed the genetic correlation between the dynamic cardiac shape atlas and previously published end-diastolic shape atlas using the software tool LDSC[53] (v1.0.1). All dynamic cardiac shape lead variants and high LD proxies ($r^2 > 0.8$) were also searched within the summary statistics of the end-diastolic shape GWAS, and results of variants with the lowest P-value among the 11 end-diastolic PCs are reported and shared signals across the cardiac atlases are indicated.

Pleiotropy and PheWAS analyses

To assess novelty of the EDES GWAS results and identify which genetic signals were not previously reported for cardiovascular traits, we collated a list of all genome-wide significant variants and high LD proxies ($r^2 > 0.8$) from a literature review of cardiac trait (cardiovascular diseases, electrocardiogram and measures of cardiac structure and function) GWAS and in the GWAS Catalog[67]. If an EDES GWAS lead variant was within 500kb of a previously reported SNV associated with a cardiovascular trait, and is in LD $r^2 \geq 0.1$, the association is reported.

We performed a phenome-wide association study (PheWAS) using the R package PheWAS[68] (version 0.99.6.1) to assess relationships between dynamic cardiac shape PC variants and curated phecodes for clinical conditions (only including case numbers ≥200), and to test PRS for these PCs with the same phecodes. The analysis was performed on UK Biobank individuals not included in the GWAS, and was adjusted for age, sex and the first 10 genetic principal components. A Bonferroni corrected threshold (number of phecodes tested $0.05/325 = 1.54 \times 10^{-4}$) was used to declare significance.

Polygenic risk scoring

We used PRSice-2[69] (version 2.3.5) to calculate each PRS, summing the dosage of each dynamic cardiac shape lead variant allele weighted by effect size (from GWAS) in the full UK Biobank genotyping cohort of 487,409 individuals. Associations were calculated through logistic regression of standard deviation increase in standardized PRS against cardiometabolic disease incidence in 447,408 unrelated (kinship pairs < 0.0884) individuals not included in the GWAS cohort. Disease outcomes were AF, AVB, HF, IHD, stroke and T2D (*Supplementary Methods*). Logistic regression models were adjusted for covariates identified to be significant for each disease through stepwise regression, selecting from age, sex, height, BMI, alcohol consumption, systolic and diastolic blood pressures, smoking status, LDL and mean triglyceride levels (*Supplementary Table 1*), the genetic array used and the first 15 genetic principal components. For the analysis the first visit covariate data was used. A P-value threshold of 0.00833 was used to define significant associations (Bonferroni corrected 0.05/number of diseases).

Mendelian Randomization

To explore the directionality and potential causality underlying significant associations between dynamic cardiac shape PCs and cardiometabolic diseases, Mendelian randomization (MR) analyses were performed using the TwoSampleMR[70] R package (version 0.6.6). PC-disease pairs selected for MR were based on statistically significant associations identified in regression analyses of dynamic shape PCs with prevalent and/or incident disease (*Supplementary methods*).

For associations with prevalent disease, where disease-related remodeling could influence cardiac
shape, MR analyses were conducted with disease status as the exposure and dynamic cardiac shape
PCs as the outcome. Conversely, for associations with incident disease, where cardiac shape may
confer risk of future disease, MR analyses were performed with dynamic cardiac shape PCs as the
exposure and disease incidence as the outcome. Additional methodological details, including
instrument selection, sensitivity analyses, and assessment of pleiotropy and heterogeneity, are
provided in the *Supplementary methods*.

Results

An overview of the study design is shown in *Figure 1*, with demographic details of the imaging and
full UKB cohorts provided in *Table 1*. Of 45,683 individuals with suitable CMR images, 41,659 passed
shape quality control and were included in the dynamic cardiac shape atlas. Fourteen PCs, each
explaining > 1% of total variance were retained, jointly accounting for 83.3% of overall shape
variability (*Table 2*). Genetic and shape data were available in 36,992 participants with complete
covariate data.

Since PCA is an unsupervised dimension reduction method, individual PCs are not directly
interpretable in terms of traditional measures. However, visual inspection of the PCs revealed that
most can be associated with biologically interpretable patterns of cardiac structure and function
(*Figure 2*). PC1 reflected overall heart size and was the dominant source of morphological variation in
the population, consistent with the absence of size correction during Procrustes alignment[47].
Subsequent PCs therefore captured dynamic shape variation independent of global size. We
observed several PCs that reflect functional remodeling: PC2 (10.62% variance) was associated with
systolic excursion of the mitral and tricuspid annular planes (MAPSE/TAPSE); PC9 (2.08%) was related
to LV basal systolic excursion; PC13 (1.14%) represented global biventricular ejection fraction and
PC14 (1.04%) reflected variation in relative ventricular size and ejection fraction. These
interpretations are summarized in Table 2, Figure 2, and can be further visualized in *Supplementary*
Movies 1-42.

Relationships with standard CMR measures, cardiovascular risk factors and biventricular ED shape atlas

Correlations between dynamic shape PCs and standard CMR measures demonstrated both shared
and complementary information (*Supplementary Figure 1*). PC1 showed strong correlations with
volumetric measures and LV mass (r = 0.88-0.95). In contrast, function-related PCs exhibited only
moderate or weak correlations with standard metrics. PC13 (biventricular ejection fraction)
correlated moderately with LVEF and RVEF (r = -0.49 and -0.44), while PC2 (MAPSE/TAPSE) showed

weak correlations (r = 0.18 and 0.15) with LVEF and RVEF, indicating that dynamic shape features

capture aspects of function not fully represented by standard CMR measures

Associations with cardiometabolic risk factors were heterogeneous (*Supplementary Figure 2*). PC1

was strongly associated with sex and age (r = 0.73 and 0.72), whereas several PCs, such as PC9 (LV

basal systolic excursion) showed weaker relationships with classical risk factors (r<0.3), indicating

that established epidemiological factors do not explain variation in biventricular shape and motion.

Comparisons with our previously published ED shape atlas[41] showed high concordance for size-

related PCs (PC1, r = 0.98) and moderate correlations for selected geometric features (*Supplementary*

Figure 3). In contrast, key functional PCs (e.g. PC2 and PC13) showed weak correlations with ED-only

PCs, confirming that the dynamic atlas captures additional information derived from systolic

deformation.

Associations with cardiometabolic diseases

Dynamic shape PCs were significantly associated with all six prevalent cardiometabolic diseases

(*Supplementary Table 3*) after Bonferroni correction (*Figure 3*). Multiple PCs were associated with

prevalent IHD, AF, and HF, often with patterns of risk-increasing and protective effects consistent

with clinical expectations. Associations were also observed for AVB and T2D.

For incident outcomes, five diseases showed significant associations, excluding stroke (*Figure 3,*

Supplementary Table 4). Interestingly, 13 PCs were associated with incident AVB, all in a risk-

increasing direction. Several PCs showed discordant directions of association between prevalent and

incident disease, consistent with a distinction between disease-related and shape-mediated disease

susceptibility.

Functionally interpretable PCs showed particularly strong effects. Increased systolic annular

excursion (PC2) was protective for prevalent IHD (OR 0.71, CI 0.67-0.74) but strongly associated with

increased risk of incident IHD (HR 3.01, CI 2.64-3.42). Similarly, reduced ejection fraction captured by

PC13 and PC14 was associated with markedly increased risk of incident HF and IHD (*Figure 3*).

Modeling incident cardiometabolic disease risk prediction

Inclusion of dynamic shape information from PC2 (valve annular plane systolic excursion) improved

prediction accuracy of time to event for incident IHD beyond standard CMR and clinical measures

alone (C-index 0.67 [CI 0.66-0.68], 0.63 [CI 0.62-0.64] respectively). The combined model includes

PC2 alongside sex, age, SBP, HDL levels, LVESV, $LVM_{systolic}$ and global longitudinal strain measured in

both the 3 and 4 chamber views. The accuracy for predicting time to incident diabetes also improved

when including PC2 in a model alongside BMI and triglyceride levels (C-index 0.65 [CI 0.63-0.67]),

where the CMR model selected BMI, triglyceride levels, HDL levels and right ventricular septal global

circumferential strain (C-index 0.59 [CI 0.56-0.61]). Cox regression models for predicting time to

incident AF, stroke and AVB failed to meaningfully predict time to event with either model. The

model for HF did not include dynamic shape information as a predictor in the final model. Variables

selected for all models are reported in *Supplementary Table 5.* Results for all models are reported in

Supplementary Table 6.

Genetic architecture of dynamic cardiac shape

All 14 PCs were heritable (h^2 = 12.3-36.9%, *Supplementary Table 7*). GWAS identified 75 genome-

wide significant loci across the PCs (Table 3, Figure 4), with minimal evidence of confounding (λ =

1.05 - 1.15). Manhattan, locus zoom, and QQ plots are available in *Supplementary Figures.* Genetic

correlations among PCs were modest to moderate (*Supplementary Table 8*), reflecting partially

shared but distinct genetic influences.

Comparison with ED shape GWAS demonstrated substantial overlap for size and geometry-related

PCs, but limited genetic correlation for functional PCs such as PC2 (MAPSE/TAPSE) and PC13 (ejection

fraction (*Supplementary Table 9)*. Of the 77 lead signals (two independent signals at discovered loci),

20 were genome-wide significant in the ED shape GWAS, and 13 demonstrated suggestive

significance (5×10^{-8} < P < 1×10^{-6}). Thirty lead signals were 1×10^{-6} < P < 1×10^{-3} and 14 had nominal

significance 1×10^{-3} < P < 0.05 (*Supplementary Table 10)*. Moreover, of the 77 lead signals, 14 of which

had not previously been implicated in cardiac traits, and 8 were entirely novel across published

GWAS at time of analysis (*Supplementary Table 11, Supplementary Table 12*).

Functional annotation identified two non-synonymous missense variants, one was predicted to be

possibly damaging with PolyPhen (rs2234962, chr10:121429633:T>C, *BAG3,* PCs 1, 10 and 13) and

one was predicted to be probably damaging (rs26821, chr5:102520400:A>G, *PPIP5K2*, PC7)

(*Supplementary Table 13)*. Twenty-two variants were identified as eQTLs in aortic artery, coronary

artery, left ventricle and atrial appendage tissues[71], of which twenty had support for colocalization

(PP4 > 0.75)[58] (*Supplementary Table 14)*. Transcriptome-wide analysis identified 103 genes (P < 3.1 x

10^{-6}, Bonferroni corrected) mapping to the boundaries of 40 loci (*Supplementary Table 15)*. Finally,

280 Hi-C interactions were identified at 45 of the lead GWAS variants, summarized in *Supplementary*

Table 16. Integrative gene prioritization including those genes identified by the aforementioned tools

alongside results from PoPs, identified 77 candidate genes (*Supplementary Table 17)*, enriched for

pathways related to cardiac development (P_{adj} = 2.79×10^{-5}), muscle structure (P_{adj} = 3.53×10^{-4}),

contractile function (P_{adj} = 4.45×10^{-4}, *Supplementary Table 18)*.

Rare variant burden testing implicated established cardiomyopathy genes (e.g. *TTN for PC1, FHOD3*

for PC10), providing convergent evidence with common variant findings (*Supplementary Table 19*).

Five additional genes not identified in the common-variant GWAS showed evidence of rare variants

driving associations (P < 2.79x10^{-6}); *RBM20* and *VPS25* for PC1 (overall heart size), *SMARCAD1* for

PC3 (ventricular sphericity), *NKAPD1* for PC7 (septal position), *CSRP3* for PC14 (relative ventricular

size and ejection fraction). There was significant evidence that multiple rare missense variants were

driving the associations at *TTN* and *SMARCAD1* (*Supplementary Table 19*).

Polygenic risk and causal inference

PRS derived from dynamic shape PCs were associated with a broad range of cardiovascular

phenotypes in PheWAS, predominantly within the circulatory system (*Supplementary Table 20*). PRS

for reduced biventricular ejection fraction (PC13) showed strong associations with HF phecodes (OR

1.06, 1.07, P = 2.74x10^{-8} – 6.19x10^{-7}), while PRS for reduced annular excursion (PC2) was associated

with ischemic and hypertensive phenotypes, despite comprising only two variants (*Supplementary*

Table 21).

We also explored relationships between dynamic cardiac shape PC PRS with prevalent and incident

cardiometabolic diseases (*Figure 5*). There were seven significant associations between PC PRS and

prevalent disease (P < 0.0083). Four were associated with prevalent IHD; PC12 (relative left

ventricular size) in a risk conferring direction (OR 2.46, CI 1.60-3.78) and PCs 2 (MAPSE/TAPSE), 5

(lateral-septal width, OR 0.45, CI 0.29-0.71) and 6 (left ventricular length, OR 0.75, CI 0.62-0.92) as

protective, two with prevalent AF; PCs 6 (LV length) and 10 (right ventricular ejection fraction) (OR

1.73 [CI 1.28-2.37]; OR 1.92 [CI 1.26-2.93]), and one with HF; PC8 (tricuspid valve opening size) (OR

4.71, CI 1.53-14.48) (*Supplementary Table 22*).

Reviewing results from testing of PC PRS with incident disease highlighted that the strongest

associations were with incident HF. There were five PC PRS significantly associated with HF: PCs 1

(heart size, OR 1.67, CI 1.36-2.05), 11 (rounder ventricular apex, OR 1.85, CI 1.45-2.36) and 13 (global

biventricular ejection fraction, OR 2.05, CI 1.67-2.51) in a risk-conferring direction and PCs 2

(MAPSE/TAPSE, OR 0.41, CI 0.27-0.62) and 3 (ventricular sphericalization, OR 0.76, CI 0.65-0.88) as

protective. Four PRS were significantly associated with incident AF; PCs 10 (right ventricular ejection

fraction, OR 1.46, CI 1.19-1.79) and 11 (OR 1.48, CI 1.22-1.80) in a risk-conferring direction and PCs 1

(heart size, OR 0.75, CI 0.63-0.88) and 3 (OR 0.66, CI 0.58-0.75) as protective. A full summary of the

significant PRS associations can be found in *Supplementary Table 23*.

MR supported a robust causal effect of reduced biventricular ejection fraction (PC13) on HF risk, with

consistent estimates across multiple methods (including Inverse variance weighted β 0.492, P 6x10^{-7}

and Weighted median β 0.408, P 4.2x10^{-5}) and no evidence of horizontal pleiotropy. Additional

significant causal relationships were observed with disease as the exposure and dynamic cardiac

shape as the outcome (reporting inverse variance weighted results, full results in *Table 4*); between

T2D and PCs 1 (overall heart size) (β -0.05, P 0.003) and 12 (relative LV size) (β 0.04, P 0.008);

between IHD and PC9 (LV basal systolic excursion) (β -0.06, P 0.008), and between HF and PC14

(relative ventricular size and ejection fraction) (β 0.1, P 0.004) (sensitivity analyses in *Supplementary*

Table 24). Full MR results are presented in *Supplementary Tables 25-27*.

Discussion

Quantifying dynamic cardiac shape through statistical shape atlasing provides a complementary

framework for studying cardiac disease-morphology relationships. By jointly modeling ventricular

geometry at ED and ES, dynamic shape phenotypes capture not only static morphology but also

functional deformation during contraction. Previously, we showed that these static shape

phenotypes have substantially stronger associations with prevalent cardiometabolic diseases than

conventional CMR measures, including ejection fraction, strain, and valve excursions[42]. Here, we

identified dynamic shape components that are significantly associated with prevalent and incident

cardiometabolic disease, influenced by expression of novel genetic loci, PRS of which are also

predictive of incident HF and AF, and which are causal for HF by Mendelian randomization. We also

improve prediction of incident IHD when adding PC13 (ejection fraction) to standard CMR measures

and covariates versus CMR measures and covariates alone.

The dynamic shape atlas builds directly on previous work based on ED shape alone. As expected,

significant correlations were observed between ED and dynamic shape PCs, particularly for

components capturing global cardiac size. However, beyond the first PC, many dynamic shape PCs

showed only modest phenotypic and genetic correlation with ED PCs, indicating that the inclusion of

ES information introduces genuinely new variation related to cardiac function. This is further

supported by the observation that all dynamic shape PCs demonstrated some degree of genetic

signal in the ED GWAS, while the dynamic atlas substantially increased discovery power. Several

dynamic shape PCs captured functional features closely aligned with established clinical metrics. PC2

reflected longitudinal annular motion analogous to MAPSE and TAPSE, while PC13 captured variation

resembling biventricular ejection fraction. Despite these similarities, correlations with standard

measures were incomplete, indicating that dynamic shape phenotypes encode complementary

information about cardiac mechanics that is not fully captured by standard CMR metrics.

Strong associations were observed between both prevalent and incident IHD and several dynamic

cardiac shape PCs, particularly those capturing functional variation (PCs 2, 9, 13 and 14). Importantly,

the direction of these associations consistently reflected impaired cardiac function, including

reduced annular plane systolic excursion (PC2) and reduced biventricular ejection fraction (PC13).

This association is also seen in the PRS for PC2, however there is disagreement in the direction of

effect between the PC and IHD and the PC PRS and IHD which could be attributed to the low percent

heritability explained by the two genome-wide significant variants identified for PC2 (0.5%). While

IHD is primarily driven by coronary artery pathology, which is not directly captured by ventricular

shape atlases, these findings demonstrate that ventricular geometry and systolic deformation

encode meaningful information about IHD risk. There is also evidence that PC2 provides

complementary information to CMR measures when predicting incident IHD.

Diabetes has long been associated with characteristic patterns of cardiac remodeling, including

reduced ventricular volumes, increased myocardial mass, and altered systolic performance[72,73].

Consistent with prior studies, we observed significant associations between multiple dynamic shape

PCs and prevalent T2D (PCs 1, 2, 8, 12, 13), extending our previous findings based on ED shape

alone[41]. Some of these observations are supported by MR, with a significant causal relationship

observed between T2D on PCs 1 (overall heart size) and 12 (relative LV size). Importantly, dynamic

shape PCs capturing both size and functional variation were associated with T2D, highlighting the

importance of systolic remodeling in metabolic heart disease. Associations with incident T2D were

also observed for all dynamic shape PCs, as well as between T2D and the PRS for PCs 2 and 11,

reinforcing the close link between cardiac morphology and metabolic dysfunction [72,74-77]. Together,

these findings support the concept that cardiac shape and function reflect a continuum of metabolic

stress and insulin resistance[78-82]. Given the difficulty of directly measuring insulin resistance, dynamic

cardiac shape phenotypes may serve as informative imaging-derived biomarkers of subclinical

metabolic dysfunction.

There were substantial associations observed between cardiac shape PCs and HF in the models using

both the PCs and PC PRS. PCs 1-8, 12-14 had significant association with prevalent HF, of which the

association between prevalent HF and PC8 (tricuspid valve opening size) is mirrored in the PRS

results, suggesting a remodeling effect of HF reflecting in dynamic shape. All PCs were significantly

associated with incident HF, relationships that were also observed in PRS for PCs 1, 2, 3, 11 and 13,

suggesting that dynamic cardiac shape can predispose future HF events. In testing the causality of

these associations in MR, a significant causal effect was observed of HF on PC14 (relative ventricular

size and ejection fraction), and of PC13 (ejection fraction) on HF. Importantly, the incomplete

correlation between PC13 and imaging-derived ejection fraction suggests that this phenotype

captures additional functional information relevant to HF beyond standard measures.

Dynamic cardiac shape PCs demonstrated moderate-to-high heritability and yielded substantially more genome-wide significant loci than previous ED shape analysis. In total, 75 loci were identified, with 14 genetic signals being novel for cardiac traits. Importantly, even for PCs closely related to ED morphology, such as overall heart size, the inclusion of systolic information increased the number of associated loci, highlighting the added genetic signal captured by dynamic phenotyping.

Several novel loci provided candidate genes with established roles in cardiac development, structure, and function, including pathways related to myocardial architecture and contractile mechanisms. In particular, PCs capturing smaller proportions of total variance, reflecting more localized or functional features, had a higher number of associations with novel loci, whereas PCs explaining larger variance overlapped more strongly with known cardiac structure and function traits. This pattern suggests that dynamic shape atlasing enables the discovery of genetic influences on subtler aspects of cardiac mechanisms that are not well represented by traditional imaging phenotypes.

Novel signals for cardiac traits included: rs12494109 identified for PC5 (lateral-septal width), the candidate gene is *Wingless-Type MMTV Integration Site Family, Member 5A*, this is a gene implicated in developmental processes during embryogenesis, associated with congenital right ventricular outflow tract obstruction in autosomal recessive Robinow syndrome[83,84], and mouse models exhibit a double outlet right ventricle, atrioventricular septal defect and left ventricular and pulmonary arterial hypoplasia[85].

Two variants, rs32841 identified for PC7 (septal position) with potential candidate gene *Gypsy Retrotransposon Integrase 1* and rs12939170 identified for PC8 (tricuspid valve opening size) with candidate gene *Replication Protein A1* had knockout mouse models with abnormal cardiac morphology[86] – knockout mice with *Gypsy Retrotransposon Integrase 1* had abnormal heart shape, and knockout mice with *Replication Protein A1* had increased heart weight.

Several additional candidate genes were indicated from gene-burden testing, of these some are known cardiomyopathy genes. One example is *Cysteine And Glycine Rich Protein 3 (CRSP3)*, rare variants in this gene are associated with PC14 (left ventricular size and reduced ejection fraction). This gene encodes a muscle LIM protein which is important for cardiac and skeletal muscle structure and function and is a regulator in sarcomere assembly and contraction[87]. A rare variant was associated in *Vacuolar Protein Sorting 25 Homolog (VPS25)*, *VPS25* encodes a protein that functions in sorting of ubiquitinated membrane proteins during endocytosis, has mouse models with decreased heart weight and hemorrhaging, and has been associated with frontotemporal dementia[88].

Conclusion

In conclusion, dynamic statistical shape atlasing captures cardiac shape variation across the cardiac cycle together with functional deformation, providing robust and interpretable imaging-derived phenotypes that encapsulate substantially more information from CMR than traditional summary measures. Building on previous ED biventricular atlases, this work demonstrates the added value of incorporating systolic information to define shape components that jointly reflect cardiac morphology and function. These dynamic shape PCs show biologically plausible associations with both prevalent and incident cardiometabolic disease and improve disease prediction when added to standard CMR-derived metrics. In genetic analyses, dynamic shape PCs enhance locus discovery compared with ED shape alone, identifying additional variants, including loci not previously implicated in cardiovascular traits. PRS constructed from these variants were also predictive of cardiometabolic outcomes. Together, these findings establish dynamic cardiac shape atlasing as a powerful and interpretable framework for integrating cardiac structure, function, genetics, and disease risk.

In future work this statistical shape atlasing methodology can be applied to more varied cohorts to explore diseases such as cardiomyopathies which are under-represented in UK Biobank, as well as exploring dynamic shape variation within the population due to factors such as sex, age or ancestry. The capacity for dynamic cardiac shape to predict incident cardiometabolic disease can be further explored with more specific datasets, and leveraging the longitudinal repeat imaging data from UK Biobank to assess the clinical utility of these imaging-derived phenotypes.

Ethics approval

This study complies with the Declaration of Helsinki; the work was covered by the ethical approval for UK Biobank studies from the NHS National Research Ethics Service on 17th June 2011 (Ref 11/NW/0382) and extended on 18 June 2021 (Ref 21/NW/0157) with written informed consent obtained from all participants.

Acknowledgements

This research was conducted using the UK Biobank Resource under Application Number 2964. The work uses data provided by patients and collected by the NHS as part of their care and support. This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20029). Copyright © (2022), NHS Digital. Re-used with the permission of the NHS Digital [and/or UK Biobank]. All rights reserved. Barts Charity (G-002346) contributed to fees required to access UK Biobank data [access application #2964]. JR acknowledges funding by the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) for fellowship RYC2021-031413-I. RB, SEP and PBM acknowledge the support of the National Institute for Health and Care Research (NIHR) Barts Biomedical Research Centre (NIHR203330); a delivery partnership of Barts Health NHS Trust, Queen Mary University of London, St George's University Hospitals NHS Foundation Trust and St George's University of London. WJY acknowledges the NIHR Integrated Academic Training program, which supports his Academic Clinical Lectureship post. KU acknowledges support from a British Heart Foundation 4-year PhD studentship (FS/4yPhD/F/23/34196).

Contributions

R.B., J.R., A.Y., and P.B.M. conceived and designed the experiments, R.B., performed the experiments, R.B., and K.U. performed statistical analysis, R.B., J.R., A.Y., and P.B.M. analysed the data, W.J.Y., J.R., A.Y., and P.B.M. contributed reagents/materials/analysis tools, J.R., A.Y., and P.B.M. jointly supervised the research, R.B., J.R., A.Y., and P.B.M. wrote the paper and W.J.Y and S.E.P. provided critical review of the manuscript.

References

1. Leancă, S. A. *et al.* Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction. *Life Basel Switz.* **13**, (2023).

2. Calvieri, C. *et al.* Left Ventricular Adverse Remodeling in Ischemic Heart Disease: Emerging Cardiac Magnetic Resonance Imaging Biomarkers. *J. Clin. Med.* **12**, (2023).

3. Del Buono, M. G. *et al.* Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling. *Curr. Probl. Cardiol.* **48**, 101215 (2023).

4. Bhatt, A. S., Ambrosy, A. P. & Velazquez, E. J. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. *Curr. Cardiol. Rep.* **19**, 71 (2017).

5. Eskerud, I., Gerdts, E., Larsen, T. H. & Lønnebakken, M. T. Left ventricular hypertrophy contributes to Myocardial Ischemia in Non-obstructive Coronary Artery Disease (the MicroCAD study). *Int. J. Cardiol.* **286**, 1–6 (2019).

6. Khalid, K. *et al.* Correlation of Coronary Artery Disease and Left Ventricular Hypertrophy. *Cureus* **13**, e17550 (2021).

7. Raman, B., Bluemke, D. A., Lüscher, T. F. & Neubauer, S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. *Eur. Heart J.* **43**, 1157–1172 (2022).

8. Merlo, A. *et al.* Right Ventricular Dysfunction before and after Cardiac Surgery: Prognostic Implications. *J. Clin. Med.* **13**, 1609 (2024).

9. Medrano-Gracia, P. *et al.* Left ventricular shape variation in asymptomatic populations: the multi-ethnic study of atherosclerosis. *J. Cardiovasc. Magn. Reson.* **16**, 56 (2014).

10. Corden, B. *et al.* Relationship between body composition and left ventricular geometry using three dimensional cardiovascular magnetic resonance. *J. Cardiovasc. Magn. Reson.* **18**, 32–32 (2016).

11. Mauger, C. *et al.* Right ventricular shape and function: cardiovascular magnetic resonance reference morphology and biventricular risk factor morphometrics in UK Biobank. *J. Cardiovasc. Magn. Reson.* **21**, 41 (2019).

12. Gilbert, K., Mauger, C., Young, A. A. & Suinesiaputra, A. Artificial Intelligence in Cardiac Imaging With Statistical Atlases of Cardiac Anatomy. *Front. Cardiovasc. Med.* **7**, 102–102 (2020).

13. de Marvao, A., Dawes, T. J. W. & O'Regan, D. P. Artificial Intelligence for Cardiac Imaging-Genetics Research. *Front. Cardiovasc. Med.* **6**, (2020).

14. Mauger, C. A. *et al.* Multi-Ethnic Study of Atherosclerosis: Relationship between Left Ventricular Shape at Cardiac MRI and 10-year Outcomes. *Radiology* 220122–220122 (2022) doi:10.1148/radiol.220122.

15. Harold, S., A., H. G. & A., T. F. Heritability of Blood Pressure and Hemodynamics in African- and European-American Youth. *Hypertension* **41**, 1196–1201 (2003).

16. Bella, J. N. *et al.* Heritability of left ventricular dimensions and mass in American Indians: The Strong Heart Study. *J. Hypertens.* **22**, (2004).

17. Busjahn, C. A. *et al.* Heritability of left ventricular and papillary muscle heart size: a twin study with cardiac magnetic resonance imaging. *Eur. Heart J.* **30**, 1643–1647 (2009).

18. Jin, Y. *et al.* Heritability of left ventricular structure and function in Caucasian families. *Eur. J. Echocardiogr.* **12**, 326–332 (2011).

19. Aung, N. *et al.* Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated With Cardiac Morphogenesis and Heart Failure Development. *Circulation* **140**, 1318–1330 (2019).

20. Aung, N. *et al.* Genome-wide association analysis reveals insights into the genetic architecture of right ventricular structure and function. *Nat. Genet.* **54**, 783–791 (2022).

21. Aung, N. *et al.* Genome-Wide Analysis of Left Ventricular Maximum Wall Thickness in the UK Biobank Cohort Reveals a Shared Genetic Background With Hypertrophic Cardiomyopathy. *Circ. Genomic Precis. Med.* **16**, e003716–e003716 (2023).

22. Pirruccello, J. P. *et al.* Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. *Nat. Commun.* **11**, (2020).

23.   Pirruccello, J. P. *et al.* Genetic analysis of right heart structure and function in 40,000 people.
Nat. Genet. **54**, 792–803 (2022).

24.   Vukadinovic, M. *et al.* Deep learning-enabled analysis of medical images identifies cardiac
sphericity as an early marker of cardiomyopathy and related outcomes. *Med N. Y. N* **4**, 252-
262.e3 (2023).

25.   Lu, C. *et al.* New Genetic Loci Implicated in Cardiac Morphology and Function Using Three-
Dimensional Population Phenotyping. *Circ. Genomic Precis. Med.* **18**, e005116 (2025).

26.   Tadros, R. *et al.* Shared genetic pathways contribute to risk of hypertrophic and dilated
cardiomyopathies with opposite directions of effect. *Nat. Genet.* **53**, 128–134 (2021).

27.   Biddinger, K. J. *et al.* Rare and Common Genetic Variation Underlying the Risk of Hypertrophic
Cardiomyopathy in a National Biobank. *JAMA Cardiol.* **7**, 715–722 (2022).

28.   Zheng, S. L. *et al.* Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general
population and across clinical settings. *Nat. Genet.* **57**, 563–571 (2025).

29.   Soh, C. H., Xiang, R., Takeuchi, F. & Marwick, T. H. Use of Polygenic Risk Score for Prediction of
Heart Failure in Cancer Survivors. *JACC CardioOncology* **6**, 714–727 (2024).

30.   Haller, P. M. *et al.* A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of
Cardiovascular Risk. *J. Am. Coll. Cardiol.* **86**, 860–873 (2025).

31.   Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with
risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).

32.   Weng, L.-C. *et al.* Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial
Fibrillation. *Circulation* **137**, 1027–1038 (2018).

33.   Segan, L. *et al.* Combining polygenic and clinical risk scores in atrial fibrillation risk prediction:
Implications for population screening. *Heart Rhythm* **22**, 1906–1914 (2025).

34.   Läll, K., Mägi, R., Morris, A., Metspalu, A. & Fischer, K. Personalized risk prediction for type 2
diabetes: the potential of genetic risk scores. *Genet. Med.* **19**, 322–329 (2017).

35.   Mars, N. *et al.* Polygenic and clinical risk scores and their impact on age at onset and prediction
of cardiometabolic diseases and common cancers. *Nat. Med.* **26**, 549–557 (2020).

36.   Ning, C. *et al.* Genome-wide association analysis of left ventricular imaging-derived phenotypes
identifies 72 risk loci and yields genetic insights into hypertrophic cardiomyopathy. *Nat.*
Commun. **14**, 7900–7900 (2023).

37.   Meyer, H. V. *et al.* Genetic and functional insights into the fractal structure of the heart. *Nature*
https://doi.org/10.1038/s41586-020-2635-8 (2020) doi:10.1038/s41586-020-2635-8.

38.   Radhakrishnan, A. *et al.* Cross-modal autoencoder framework learns holistic representations of
cardiovascular state. *Nat. Commun.* **14**, 2436 (2023).

39.   Bonazzola, R. *et al.* Unsupervised ensemble-based phenotyping enhances discoverability of
genes related to left-ventricular morphology. *Nat. Mach. Intell.* **6**, 291–306 (2024).

40.   Ometto, S. *et al.* Hundreds of cardiac MRI traits derived using 3D diffusion autoencoders share a
common genetic architecture. 2024.11.04.24316700 Preprint at
https://doi.org/10.1101/2024.11.04.24316700 (2025).

41.   Burns, R. *et al.* Genetic basis of right and left ventricular heart shape. *Nat. Commun.* **15**, 9437
(2024).

42.   Burns, R. *et al.* Relationships between heart shape, function, and disease in 38,858 UK biobank
participants. *J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson.* **27**, 101919
(2025).

43.   Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range
of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779–e1001779 (2015).

44.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**,
203–209 (2018).

45.   Petersen, S. E. *et al.* UK Biobank's cardiovascular magnetic resonance protocol. *J. Cardiovasc.*
Magn. Reson. **18**, 8–8 (2016).

46. Mauger, C. *et al.* An Iterative Diffeomorphic Algorithm for Registration of Subdivision Surfaces:
Application to Congenital Heart Disease. in 596–599 (2018). doi:10.1109/EMBC.2018.8512394.

47. Goodall, C. Procrustes Methods in the Statistical Analysis of Shape. *J. R. Stat. Soc. Ser. B*
Methodol. **53**, 285–339 (1991).

48. van Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations
in R. *J. Stat. Softw.* **45**, 1–67 (2011).

49. Tay, J. K., Narasimhan, B. & Hastie, T. Elastic Net Regularization Paths for All Generalized Linear
Models. *J. Stat. Softw.* **106**, 1–31 (2023).

50. Friedman, J. H., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via
Coordinate Descent. *J. Stat. Softw.* **33**, 1–22 (2010).

51. Loh, P.-R. *et al.* Contrasting genetic architectures of schizophrenia and other complex diseases
using fast variance-components analysis. *Nat. Genet.* **47**, 1385–1392 (2015).

52. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large
cohorts. *Nat. Genet.* **47**, 284–290 (2015).

53. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in
genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

54. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait
analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).

55. Ng, P. C. & Henikoff, S. Predicting Deleterious Amino Acid Substitutions. *Genome Res.* **11**, 863–
874 (2001).

56. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense
mutations using PolyPhen-2. *Curr. Protoc. Hum. Genet.* **Chapter 7**, Unit7.20-Unit7.20 (2013).

57. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122–122 (2016).

58. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association
Studies Using Summary Statistics. *PLOS Genet.* **10**, e1004383–e1004383 (2014).

59. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression
variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825–1825 (2018).

60. Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB.
Genome Res. **22**, 1790–1797 (2012).

61. Schmitt, A. D. *et al.* A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions
in the Human Genome. *Cell Rep.* **17**, 2042–2059 (2016).

62. Jung, I. *et al.* A compendium of promoter-centered long-range chromatin interactions in the
human genome. *Nat. Genet.* **51**, 1442–1449 (2019).

63. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes
underlying complex traits and diseases. *Nat. Genet.* **55**, 1267–1276 (2023).

64. Blake, J. A. *et al.* Mouse Genome Database (MGD): Knowledgebase for mouse–human
comparative biology. *Nucleic Acids Res.* **49**, D981–D987 (2021).

65. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826–1826 (2017).

66. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

67. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies,
targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–D1012 (2019).

68. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools for
phenome-wide association studies in the R environment. *Bioinforma. Oxf. Engl.* **30**, 2375–2376
(2014).

69. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale data.
GigaScience **8**, giz082 (2019).

70. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human
phenome. *eLife* **7**, e34408 (2018).

71. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585
(2013).

72. Jensen, M. T. *et al.* Changes in Cardiac Morphology and Function in Individuals With Diabetes
Mellitus. *Circ. Cardiovasc. Imaging* **12**, e009476 (2019).

73. Kanamori, H. *et al.* Morphological characteristics in diabetic cardiomyopathy associated with
autophagy. *J. Cardiol.* **77**, 30–40 (2021).

74. Bertrand, A., Lewis, A., Camps, J., Grau, V. & Rodriguez, B. Multi-modal characterisation of early-
stage, subclinical cardiac deterioration in patients with type 2 diabetes. *Cardiovasc. Diabetol.* **23**,
371 (2024).

75. Devereux, R. B. *et al.* Impact of Diabetes on Cardiac Structure and Function. *Circulation* **101**,
2271–2276 (2000).

76. Jørgensen, P. G. *et al.* Impact of type 2 diabetes and duration of type 2 diabetes on cardiac
structure and function. *Int. J. Cardiol.* **221**, 114–121 (2016).

77. Sørensen, M. H. *et al.* Cardiac perfusion, structure, and function in type 2 diabetes mellitus with
and without diabetic complications. *Eur. Heart J. - Cardiovasc. Imaging* **21**, 887–895 (2020).

78. Witteles, R. M. & Fowler, M. B. Insulin-Resistant Cardiomyopathy. *JACC* **51**, 93–102 (2008).

79. Kidambi, S., Kotchen, J., Krishnaswami, S., Grim, C. & Kotchen, T. Cardiovascular correlates of
insulin resistance in normotensive and hypertensive African Americans (Hemodynamic
correlates of insulin resistance). *Metabolism.* **60**, 835–842 (2011).

80. Banerjee, D. *et al.* Insulin Resistance and Risk of Incident Heart Failure. *Circ. Heart Fail.* **6**, 364–
370 (2013).

81. Fan, Y. *et al.* Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin
Resistance. *Diabetes Metab. J.* **48**, 19–36 (2024).

82. Sevilla-González, M. *et al.* Heterogeneous effects of genetic variants and traits associated with
fasting insulin on cardiometabolic outcomes. *Nat. Commun.* **16**, 2569 (2025).

83. Schleiffarth, J. R. *et al.* Wnt5a Is Required for Cardiac Outflow Tract Septation in Mice. *Pediatr.*
Res. **61**, 386–391 (2007).

84. Li, P. *et al.* Variants in the Regulatory Region of WNT5A Reduced Risk of Cardiac Conotruncal
Malformations in the Chinese Population. *Sci. Rep.* **5**, 13120 (2015).

85. Lo, C. Information submitted by the NHLBI Cardiovascular Development Consortium (CvDC),
Bench to Bassinet Program (B2B/CvDC). MGI Direct Data Submission (B2B/CvDC)
https://doi.org/J:175213 (2011).

86. Mouse Genome Informatics and the International Mouse Phenotyping Consortium (IMPC).
Obtaining and Loading Phenotype Annotations from the International Mouse Phenotyping
Consortium (IMPC) Database. Database Release https://doi.org/J:211773 (2014).

87. Vafiadaki, E., Arvanitis, D. A. & Sanoudou, D. Muscle Lim Protein: master regulator of cardiac and
skeletal muscle function. *Gene* **566**, 1–7 (2015).

88. Handschuh, K. *et al.* ESCRT-II/Vps25 Constrains Digit Number by Endosome-Mediated Selective
Modulation of FGF-SHH Signaling. *Cell Rep.* **9**, 674–687 (2014).

Main Figures

Figure 1. Study overview

730
731   *Graphical overview of the study cohorts and analyses performed.*
732
In blue the cohorts used in the imaging and genetics analyses with the sample size for the GWAS
indicated. In black there are graphics of the main analyses performed; correlation analyses between
dynamic shape PCs and CMR measures, cardiometabolic disease risk factors and end-diastolic PCs;
regression analyses between dynamic shape PCs and prevalent and incident cardiometabolic disease;
GWAS for dynamic shape PCs; rare variant analysis to identify rare frequency variants associated
with dynamic cardiac shape; a gene prioritization bioinformatics pipeline for identifying candidate
genes at genome-wide significant loci; polygenic risk scoring and regression analyses to calculate
associations between dynamic shape PCs and prevalent and incident cardiometabolic disease.
741
742   *Abbreviations: CMR, cardiac magnetic resonance (imaging); SNV, single nucleotide variant; QC,*
743   *quality control; GWAS, genome-wide association study; VEP, variant effect prediction; TWAS,*
744   *transcriptome-wide association study; PRS, polygenic risk score.*

745   Figure 2. Dynamic shape principal components

Visual summaries of the dynamic shape variation captured by each PC with a text description.

For each PC, the shape of the biventricular model at ±2 standard deviations from the mean shape in the direction of that PC is represented. Within each biventricular model represented, green indicates the left ventricular endocardium at end-systole, blue indicates the right ventricular endocardium at end-systole, pink indicates the epicardium at end-systole, and these same structures and end-diastole are indicated in wireframe. PC, principal component; S.D., standard deviation.

753   Figure 3 Disease associations between dynamic cardiac shape and cardiometabolic disease

754
755   *Summary plots of the significant associations between dynamic shape PCs and prevalent and incident*
756   *cardiometabolic disease.*
757
758   *On the X-axis is the relative effect of change in the PC, represented as odds-ratio for prevalent*
759   *disease and hazard ratio for incident disease. Each association between PC and disease is color*
760   *coded, with the effect represented as a dot and the 95% confidence intervals as a line. Only disease*
761   *associations which are significant (Bonferroni corrected P value < 0.05/6) are shown. The dashed red*
762   *line on the X-axis represents no effect.*
763
764   *Abbreviations: OR, odds ratio; HR, hazard ratio; AF, atrial fibrillation; AVB, significant 2nd or 3rd degree*
765   *atrioventricular block; HF, heart failure; T2D, type 2 diabetes mellitus; IHD, ischemic heart disease;*
766   *PC, principal component; PRS, polygenic risk score.*

767 Figure 4. Circos plot of GWAS results and associations with CMR measures

A circos plot summarizing the genetic basis of dynamic cardiac shape.

Visualized is a circular Manhattan plot with genome-wide association study summary statistics for
each of the 14 dynamic shape principal components overlaid. Chromosomes are divided into
segments numbered on the outside of the Manhattan plot; genomic position is along the X-axis and
Log10 P-Value on the Y-axis. The genome-wide significant variants ($P \leq 5 \times 10^{-8}$) which have been
previously reported for CMR ventricular structural and functional traits are highlighted in blue, and
genome-wide significant variants which have not been previously identified for any cardiovascular-
related trait (n=14) are highlighted in green. For each genome-wide significant variant, the candidate
gene annotated by the PoPS tool is indicated on the outside of the plot with a line pointing to the
variant position. The plot also illustrates genome-wide significant variants which have been identified
previously for CMR structural and functional measures; divided into left and right ventricular
structural and functional CMR measures. These have segments in the plot alongside the
chromosomes, color coded with lines leading to the significant variants that have been associated
with the trait. LV, left ventricular; RV, right ventricular.

785
Summary plots of the significant associations between dynamic shape PC PRS and prevalent and
incident cardiometabolic disease.

On the X-axis is the relative effect of change in the PC PRS, represented as odds-ratio for prevalent
disease and hazard ratio for incident disease. Each association between PC PRS and disease is color
coded, with the effect represented as a dot and the 95% confidence intervals as a line. Only disease
associations which are significant (Bonferroni corrected P value < 0.05/6) are shown. The dashed red
line on the X-axis represents no effect.

Abbreviations: OR, odds ratio; HR, hazard ratio; AF, atrial fibrillation; AVB, significant 2nd or 3rd degree
atrioventricular block; HF, heart failure; T2D, type 2 diabetes mellitus; IHD, ischemic heart disease;
PC, principal component; PRS, polygenic risk score.

Main Tables

Table 1. Study demographics of the imaging and full cohorts in UK Biobank

Trait	Imaging N = 41,056	Full cohort N = 487,284
Age, years	55.0 (7.6)	56.5 (8.1)
Male sex	21,366 (52.0%)	264,700 (54.2%)
Height, cm	169.6 (9.2)	168.5 (9.3)
Body mass index, kg/m^2	26.5 (4.2)	27.4 (4.8)
Systolic Blood pressure*, mmHg	138.9 (20.4)	142.9 (21.8)
Diastolic Blood pressure*, mmHg	82.7 (11.4)	84.3 (11.9)
Previous or current smoker	16,205 (39.5%)	220,084 (45.1%)
Regular alcohol use (≥3 times per week)	20,882 (50.1)	212,026 (43.4)
Serum LDL levels*, mmol/l	NA	3.8 (0.9)
Serum HDL levels*, mmol/l	NA	1.4 (0.4)
Serum triglyceride levels*, mmol/l	NA	1.75 (1.0)
Genetically inferred ancestry		
European	38,767	459,783
African	241	7,823
South Asian	455	9,731
East Asian	145	2,115
Cardiometabolic disease		
Ischemic heart disease†	6,066 (14.77, 39.56)	121,299 (24.89, 24.05)
Heart failure†	526 (1.28, 66.73)	18,384 (3.77, 10.19)
Type 2 diabetes†	2,283 (5.56, 40.21)	58,782 (12.06, 21.72)
Significant atrioventricular block†	407 (0.99, 73.46)	11,101 (2.28, 9.37)
Atrial fibrillation†	1,446 (3.52, 34.02)	31,208 (6.40, 19.79)
Stroke†	4,109 (10.00, 27.43)	65,913 (13.53, 36.43)
CMR measures		
RVEDV, ml	148.5 (35.3)	
RVESV, ml	66.6 (20.7)	
RVSV, ml	81.9 (19.7)	
RVEF, %	55.5 (7.2)	
LVEDV, ml	147.9 (33.7)	
LVESV, ml	68.9 (19.7)	
LVM, g	124.2 (26.7)	
LVSV, ml	79.0 (18.4)	
LVEF, %	53.7 (6.2)	

*Numbers are mean (standard deviation) or total number (%). *Systolic and diastolic blood pressure were adjusted for anti-hypertensive medication use by adding 15mmHg and 10mmHg, respectively. † Diseases are reported as total number of cases available in UK Biobank cohort, with the percentage of the total respective UKB cohort that are case positive and the percentage of those cases that are incident (diagnosed after the respective visit - baseline visit for the genetics cohort excluding the imaging cohort, and imaging visit for the imaging cohort) in brackets. Abbreviations: RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; RVEF, right ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; bpm, beats per minute (heart).*

 Table 2. Summary of dynamic shape PCs

PC	Biological feature	Variation direction (Higher/Lower)		Variance explained (%)
		Higher	Lower	
1	Overall heart size	Bigger heart	Smaller heart	34.07
2	Mitral and tricuspid annular plane systolic excursion	Greater degree of MAPSE/TAPSE	Lesser degree of MAPSE/TAPSE	10.62
3	Ventricular sphericalisation	Thinner and longer ventricles	Shorter and wider ventricles in anterior posterior direction	7.81
4	Left ventricular basal position	Lower mitral plane and wider RV in anterior-posterior direction	Higher mitral plane and higher angled tricuspid valve plane	5.52
5	Lateral-septal width	Narrower in the lateral septal direction	Wider in lateral septal direction	5.46
6	Left ventricular length	Longer LV length	Shorter LV length	4.22
7	Septal position	Septal position more shifted to the left	Septal position more shifted towards the right	4.02
8	Tricuspid valve opening size	Smaller tricuspid valve opening	Wider tricuspid valve opening	2.41
9	LV basal systolic excursion	Reduced MAPSE	Greater MAPSE	2.08
10	Right ventricular ejection fraction	Greater RV ejection fraction	Less RV ejection fraction	2
11	Rounder ventricular apex	Rounder apex of the ventricles	More elongated and pointed ventricular apex	1.6
12	Relative left ventricular size	Greater relative size of the LV	Smaller LV relative to the RV	1.3
13	Ejection fraction	Reduced LV and RV ejection fraction	Greater LV and RV ejection fraction	1.14
14	Relative ventricular size and ejection fraction	smaller RV, with reduced LV ejection fraction	Larger RV, greater LV ejection fraction	1.04

808   *Abbreviations: PC, principal component; LV, left ventricle; RV, right ventricle; TAPSE, tricuspid (valve) annular*
809   *plane systolic excursion.*

 Table 3. Lead genetic variants and secondary signals from genome-wide association study

PC	Nearest gene	Lead variant	CHR	Position (Hg19)	EA	NEA	MAF	BETA	SE	P value
1	ATXN2	rs653178	12	112007756	C	T	0.481	-0.037	0.004	2.70E-21
1	TTN	rs2042995	2	179558366	T	C	0.223	0.042	0.005	1.30E-18
1	BAG3	rs72840788	10	121415685	G	A	0.218	0.041	0.005	3.40E-17
1	RSPH6A	rs7257103	19	46306904	C	T	0.344	-0.03	0.004	1.30E-12
1	LSM3	rs73028849	3	14272766	G	C	0.34	0.026	0.004	2.90E-10
1	EPHB1	rs77709005	3	134444297	C	T	0.148	0.035	0.006	4.00E-10
1	MLF1	rs9810339	3	158302517	T	C	0.496	-0.025	0.004	4.30E-10
1	GOSR2	rs533030436	17	45091770	A	G	0.12	-0.038	0.006	2.20E-09
1	OBSCN	rs78529941	1	228551488	G	A	0.38	-0.024	0.004	3.00E-09
1	HLA-DRB5	rs6939900	6	31228357	C	T	0.357	0.025	0.004	3.00E-09
1	FHOD3	rs2644262	18	34223566	T	C	0.271	0.026	0.004	3.80E-09
1	LINC00964	rs34123659	8	125862029	T	TA	0.186	0.03	0.005	4.90E-09
1	CLCNKA	rs28579893	1	16347534	A	G	0.327	-0.024	0.004	5.20E-09
1	HSPA4	5:132409975_CT_C	5	132409975	CT	C	0.267	0.027	0.005	5.90E-09
1	PLEC	rs11786896	8	145018354	C	T	0.051	0.052	0.009	1.10E-08
1	PLCB3	rs71468663	11	64018104	A	AC	0.047	0.052	0.009	2.20E-08
1	CENPW	rs373980643	6	126699611	GT	G	0.457	-0.022	0.004	2.50E-08
2	EFEMP1	rs3791679	2	56096892	A	G	0.228	-0.046	0.008	1.20E-09
2	PTPN11	rs11066320	12	112906415	A	G	0.423	-0.037	0.006	7.40E-09
3	PALMD	rs1890753	1	100039519	G	C	0.478	0.043	0.007	1.00E-10
3	EN1	rs332659	2	119456238	A	C	0.326	0.044	0.007	5.30E-10
3	PALLD	rs10155248	4	169666162	T	A	0.474	-0.048	0.007	9.40E-13
3	PRDM6	rs10077410	5	122450771	G	A	0.136	0.054	0.01	2.30E-08
3	CDKN1A	rs3176326	6	36647289	G	A	0.199	-0.055	0.008	8.30E-11
3	DNMBP*	rs11190360	10	101760736	T	C	0.058	-0.082	0.014	1.30E-08
3	NRAP*	rs10749139	10	115415214	T	C	0.137	-0.055	0.01	3.80E-08
3	DIP2B	rs112716157	12	50907656	C	CA	0.414	0.051	0.007	1.30E-11
3	CRADD	rs4144499	12	94151844	C	T	0.496	-0.044	0.007	3.20E-11
3	GOSR2	rs17608766	17	45013271	T	C	0.145	0.084	0.009	1.30E-18
3	MIR196A1*	rs71366902	17	46719157	A	AT	0.206	0.045	0.008	4.20E-08
4	PRDM6	rs186749	5	122454305	A	G	0.356	0.039	0.007	2.00E-08
5	WNT5A*	rs12494109	3	55491571	C	A	0.456	0.038	0.007	4.70E-08
5	HAND2-AS1	rs12502027	4	174600223	A	G	0.362	-0.046	0.007	2.40E-10
5	PRDM6	rs398028	5	122454550	C	T	0.203	-0.052	0.009	2.20E-09
5	HLA-DRB5	rs2284174	6	30713580	T	C	0.224	-0.05	0.008	2.90E-09
5	HLA-DRB5	6:31588020_CCTCT_C	6	31588020	CCTCT	C	0.362	0.043	0.007	3.30E-09
5	CCDC91	rs2638950	12	28551567	A	G	0.244	0.044	0.008	4.30E-08
5	ADAMTSL3	rs6602994	15	84490757	T	C	0.279	0.043	0.008	2.20E-08
6	EFEMP1	rs201699038	2	56075676	AT	A	0.156	0.06	0.009	1.30E-10
6	RSRC1	rs11710570	3	158056654	T	C	0.448	0.052	0.007	1.00E-14
6	CEP85L	rs11756440	6	118993642	C	A	0.473	0.041	0.007	8.00E-10
6	TCF21	rs162185	6	134226147	T	C	0.409	-0.039	0.007	9.80E-09

6	FAM3C	rs12531355	7	121027434	C	T	0.271	0.048	0.008	2.00E-10
6	HAS2-AS1	rs62526480	8	122681022	T	C	0.406	-0.038	0.007	2.00E-08
6	DDX6*	rs12223220	11	118587888	A	G	0.175	-0.053	0.009	1.10E-08
6	ZBTB7A	rs66534382	19	4056366	G	A	0.19	0.049	0.009	9.70E-09
7	HEATR1	rs531997	1	236803402	A	G	0.179	-0.053	0.009	3.00E-09
7	PPIP5K2*	rs32841	5	102478258	A	G	0.347	0.041	0.007	2.40E-08
7	TBX3	rs10850409	12	115381740	G	A	0.268	0.044	0.008	1.30E-08
8	SGF29*	rs151091024	16	28569054	A	G	0.026	-0.13	0.022	6.40E-09
8	DPH1*	rs12939170	17	1937526	C	T	0.028	-0.115	0.021	4.60E-08
9	SLIT2*	rs6821503	4	19609401	C	T	0.263	0.042	0.008	3.90E-08
9	LZTS1-AS1*	rs7014186	8	20318812	A	C	0.115	-0.057	0.01	4.30E-08
9	MFSD14B*	9:97209762_TG_T	9	97209762	TG	T	0.108	-0.076	0.014	4.40E-08
10	MYH6	rs422068	14	23864804	T	C	0.356	-0.057	0.007	1.50E-15
10	FHOD3	18:34219777_G_GTT	18	34219777	G	GTT	0.248	0.048	0.008	1.80E-09
10	BAG3	rs17617337	10	121426884	C	T	0.218	0.047	0.008	9.70E-09
10	CMTM4	16:66690988_AT_A	16	66690988	AT	A	0.489	-0.039	0.007	2.30E-08
11	CDKN1A	rs3176326	6	36647289	G	A	0.199	0.058	0.009	4.20E-11
11	STRN	rs138934670	2	37136145	A	AAAC	0.356	0.048	0.008	1.50E-09
11	CDH13*	rs9932314	16	82881172	C	T	0.498	0.04	0.007	1.00E-08
11	ITGA1*	rs60757101	5	51603171	T	A	0.168	-0.056	0.01	2.50E-08
11	CCSER1*	rs77504602	4	92260138	C	A	0.288	-0.042	0.008	4.40E-08
12	FBN2	rs13185878	5	127962298	A	G	0.273	-0.043	0.008	1.90E-08
12	HEATR5B	rs1105014	2	37265727	G	C	0.479	-0.038	0.007	2.10E-08
13	BAG3	rs2234962	10	121429633	T	C	0.218	0.061	0.008	4.60E-14
13	LINC00964	rs34866937	8	125859850	G	A	0.314	0.054	0.007	5.90E-14
13	LSM3	rs56242556	3	14273472	C	T	0.215	-0.058	0.008	1.30E-12
13	HSPB7*	rs1048238	1	16341649	C	T	0.428	-0.041	0.007	1.30E-09
13	LDB3	rs35605324	10	88443703	G	A	0.081	0.071	0.012	6.60E-09
13	FAM86B3P	rs1915986	8	8114543	A	G	0.499	0.038	0.007	2.10E-08
14	SLC35F1	rs17079881	6	118566187	A	G	0.134	0.063	0.01	2.90E-10
14	ACTN2	rs12724121	1	236852282	A	T	0.371	-0.044	0.007	6.70E-10
14	CMSS1	rs12488245	3	99835254	T	C	0.416	-0.04	0.007	1.00E-08
14	FHOD3	18:34219777_G_GTT	18	34219777	G	GTT	0.248	0.044	0.008	4.00E-08
Conditionally independent secondary signals										
1	SLC6A6	rs34234056	3	14418444	A	G	0.494	0.021	0.004	1.10E-07
11	CDH13	rs4366697	16	83067983	G	C	0.322	0.038	0.007	2.80E-07

812   Abbreviations: PC, Principal component; CHR, chromosome; Hg19, Genome Reference Consortium Human Build
813   37 (GRCh37); EA, effect allele; NEA, non-effect allele; Beta, effect size; SE, standard error; p, probability value.

814   * indicates variant not previously reported for a cardiac trait.

815   Table 4. Significant Mendelian Randomization results

Exposure	Outcome	Method	n SNV	Beta	SE	P value	MR Egger Het P	Inverse variance weighted Het P	Pleiotropy P
PC13	HF	Inverse variance weighted	5	0.49	0.10	6.00E-07	0.04	0.08	0.86
PC13	HF	Weighted median	5	0.41	0.10	4.18E-05	0.04	0.08	0.86
T2D	PC12	Inverse variance weighted	138	0.04	0.01	0.008	0.01	0.01	0.28
T2D	PC12	Weighted median	138	0.07	0.02	3.64E-04	0.01	0.01	0.28
T2D	PC12	Weighted mode	138	0.09	0.03	0.001	0.01	0.01	0.28
T2D	PC1	Weighted mode	154	-0.05	0.02	0.003	<1E-7	<1E-7	0.14
HF	PC14	Inverse variance weighted	37	0.10	0.04	0.004	0.05	0.05	0.36
IHD	PC9	Inverse variance weighted	175	-0.06	0.02	0.008	0.20	0.21	0.75

816   *Abbreviations: PC, principal component; T2D, type 2 diabetes mellitus; HF, heart failure; IHD, ischemic heart*
817   *disease; SNV, single nucleotide variants included in analysis; SE, standard error.*